Associate Professor, Surgery, Case Western Reserve University School of Medicine
Urology
Dr. Andrew J. Stephenson, MD
|
|
Give Review
Andrew Stephenson is an expert in the field of Urology. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Andrew J. Stephenson, MD is also a published physician. He has 98 paper published. The most recent paper is: Methicillin-resistant Staphylococcus aureus in burns patients--why all the fuss? He accepts all Medicare patients.
Publications
- Surgical Salvage of Thermal Ablation Failures for Renal Cell Carcinoma.
- Re: Long-term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer.
- Management of Stage I Nonseminomatous Germ Cell Tumors.
- Are Biochemical Recurrence Outcomes Similar After Radical Prostatectomy and Radiation Therapy? Analysis of Prostate Cancer-Specific Mortality by Nomogram-predicted Ris...
- Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
- Early salvage radiotherapy following radical Prostatectomy.
- Re: Medium-term Outcomes of Active Surveillance for Localized Prostate Cancer.
- Predicting Risk of Bladder Cancer Using Clinical and Demographic Information from Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Participants.
- Active Surveillance for Low-risk Prostate Cancer in African American Men: A Multi-institutional Experience.
- Reply from Authors re: Guillaume Ploussard, James W. Catto. The Quest for an Optimal Definition of Prostate-specific Antigen Failure Following Radical Prostatectomy: T...
- Robot-assisted laparoscopic retroperitoneal lymph node dissection for left clinical stage I non-seminomatous germ cell testicular Cancer: Focus on port placement and s...
- Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate Cancer.
- Do Margins Matter? The Influence of Positive Surgical Margins on Prostate Cancer-Specific Mortality.
- Optimal Definition of Biochemical Recurrence After Radical Prostatectomy Depends on Pathologic Risk Factors: Identifying Candidates for Early Salvage Therapy.
- Controversies in the Management of Stage 1 Non-Seminomatous Germ Cell Tumors.
- Comparative outcomes of laparoscopic and open adRenalectomy for adrenocortical carcinoma: single, high-volume center experience.
- Response to the U.S. Preventative Services Task Force Decision on Prostate Cancer Screening.
- Multidisciplinary management of patients with localized Bladder cancer.
- Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity.
- Clinicians Versus Nomogram: Predicting Future Technetium-99m Bone Scan Positivity in Patients With Rising Prostate-specific Antigen After Radical Prostatectomy for Pro...
- Who should be included in a clinical trial of screening for Bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screeni...
- Prostate Cancer patients older than 70 years treated by radical prostatectomy have higher biochemical recurrence rate than their matched younger counterpart.
- Clinicopathologic Characteristics of 23 Cases of Invasive Low-grade Papillary Urothelial Carcinoma.
- The effect of sunitinib on primary Renal cell carcinoma and facilitation of subsequent surgery.
- The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation.
- Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy.
- Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
- Presacral and retroperitoneal lymph node involvement in urothelial Bladder cancer: results of a prospective mapping study.
- Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
- Inadequacy of Biopsy for Diagnosis of Upper Tract Urothelial Carcinoma: Implications for Conservative Management.
- Acceptance and Durability of Surveillance as a Management Choice in Men with Screen-detected, Low-risk Prostate Cancer: Improved Outcomes with Stringent Enrollment Cri...
- Neoadjuvant Systemic Therapy or Early Cystectomy? Single-center Analysis of Outcomes After Therapy for Patients With Clinically Localized Micropapillary Urothelial Car...
- Association of Mycoplasma hominis infection with prostate Cancer.
- Avoiding Androgen Deprivation Therapy in Men With High-risk Prostate Cancer: The Role of Radical Prostatectomy as Initial Treatment.
- Predicting 15-year prostate Cancer specific mortality after radical prostatectomy.
- Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular Cancer.
- Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy.
- Aggregate lymph node metastasis diameter and survival after radical cystectomy for invasive Bladder cancer.
- The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate Cancer treatment.
- Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular Cancer using decision analysis.
- Are nomograms needed in the management of Bladder cancer?
- Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate Cancer recurrence after radical prostatectomy.
- Prostate Cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
- Surgical resection of Renal cell carcinoma after targeted therapy.
- Utility of preoperative Renal artery embolization for management of Renal tumors with inferior vena caval thrombi.
- Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical Prostatectomy and predictions of preoperative nomogram.
- Histopathologic features and clinical outcomes in 71 cases of Bladder diverticula.
- Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the Bladder: a contemporary series.
- Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the Bladder.
- The specific definition of high risk prostate Cancer has minimal impact on biochemical relapse-free survival.
- A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate Cancer.
- Low testosterone and risk of biochemical recurrence and poorly differentiated prostate Cancer at radical prostatectomy.
- Re: Zhao et al.: External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score (Urology 2008;72:396-400).
- Systems pathology and predicting outcome after radical Prostatectomy.
- Validation of pretreatment nomograms for predicting indolent prostate Cancer: efficacy in contemporary urological practice.
- Is the Phoenix definition superior to ASTRO for predicting clinical outcomes in prostate Cancer?
- Prostate Cancer volume at biopsy predicts clinically significant upgrading.
- Is obesity associated with biochemical recurrence in patients with prostate Cancer?
- Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular Cancer.
- Squamous cell carcinoma of the Bladder: a clinicopathologic analysis of 45 cases.
- Identifying patients at risk for prostate-Cancer-specific mortality: implications for clinical trial design.
- Predicting the outcome of salvage radiation therapy for recurrent prostate Cancer after radical prostatectomy.
- Management of clinical stage I nonseminomatous germ cell testicular Cancer.
- Screening for urologic malignancies in primary care: pros, cons, and recommendations.
- Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular Cancer.
- Defining biochemical recurrence of prostate Cancer after radical prostatectomy: a proposal for a standardized definition.
- Preoperative nomogram predicting the 10-year probability of prostate Cancer recurrence after radical prostatectomy.
- Role of salvage radical prostatectomy for recurrent prostate Cancer after radiation therapy.
- Postoperative nomogram predicting the 10-year probability of prostate Cancer recurrence after radical prostatectomy.
- Management of patients with low-stage nonseminomatous germ cell testicular Cancer.
- Recovery of erectile function after salvage radical prostatectomy for locally recurrent prostate Cancer after radiotherapy.
- Retroperitoneal lymph node dissection in patients with low stage testicular Cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
- Integration of gene expression profiling and clinical variables to predict Prostate carcinoma recurrence after radical Prostatectomy.
- Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate Cancer after radiotherapy.
- Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular Cancer: impact of patient selection factors on outcome.
- Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate Cancer after radiation therapy.
- The value of radiotherapy in treating recurrent prostate Cancer after radical prostatectomy.
- Salvage therapy for locally recurrent prostate Cancer after external beam radiotherapy.
- Variations in PSA doubling time in patients with prostate Cancer on "watchful waiting": value of short-term PSADT determinations.
- Guidelines for the surveillance of localized Renal cell carcinoma based on the patterns of relapse after nephrectomy.
- The role of retroperitoneal lymph node dissection in the management of testicular Cancer.
- Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor.
- Salvage radiotherapy for recurrent prostate Cancer after radical prostatectomy.
- Gene expression profiling predicts clinical outcome of prostate Cancer.
- Complications of radical and partial nephrectomy in a large contemporary cohort.
- Utility of PSA doubling time in follow-up of untreated patients with localized prostate Cancer.
- Superior epithelial arcuate lesions with soft contact lens wear.
- The relationship of genotype to cognitive outcome in galactosaemia.
- Family physicians' knowledge of malignant melanoma.
- A gene for autosomal recessive limb-girdle muscular dystrophy maps to chromosome 2p.
- Linkage studies of HLA and primary Sjögren's syndrome in multicase families.
- Methicillin-resistant Staphylococcus aureus in burns patients--why all the fuss?
- Patterns of contraction in Human full thickness skin grafts.
- BCAN Think Tank session 3: Prevention of Bladder cancer.
- How many lymphadenectomies does it take to cure one patient?
- Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate Cancer undergoing radical prostatectomy.
- Perspectives on the natural history of recurrent prostate Cancer after radical prostatectomy, based on the response to salvage radiotherapy.
Schools
Schulich School Of Medicine At The University Of Western Ontario
Procedures Preformed
- AdRenalectomy
- Cystometry
- Cystourethroplasty with Repair of Bladder Neck with Robotic Assistance
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- View All
Conditions Treated
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- Blood in Urine (Hematuria)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Memorial Sloan-Kettering Cancer Center -
University of Western Ontario
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1366478455 | |
| NPPES Provider LastName | STEPHENSON | |
| NPPES Provider FirstName | ANDREW | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Urology | |
| Total Claim Count | 103.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1366478455 |
| Last Name Of The Provider | STEPHENSON |
| First Name Of The Provider | ANDREW |
| View All |
Similar Doctors
|
|
Dr. Christopher S. Reese, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Hui Zhu, MD |
|
|
Dr. David A. Goldfarb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael T. Barkoukis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cesar E. Ercole, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aisha K. Taylor, MD |
|
|
Dr. Joseph R. Zabell, MD |
|
|
Dr. Peter P. Stuhldreher, MD |
|
|
Debby Y. Chuang
This Doctor is OpenDoctor Recommended.
|